Deliang Guo PhD

Deliang Guo PhD
Asst ProfessorCollege of
Wiseman Hall 400 W 12th Avenue Columbus Ohio 43210
Phone:Fax: 614-247-1877
  • Experimental Therapeutics

General Research Interest

Oncogenic signaling transduction and cancer metabolism.

Research Description

Dr. Guo’s lab is focusing on EGFR/RTKs/PI3K/Akt and Ras/MEK/ERK signaling transduction and cancer metabolism. Recently he uncovered EGFR/PI3K/Akt signaling upregulates SREBP-1 activity to promote de novo fatty acid synthesis and increase cholesterol uptake in brain tumor patients, and demonstrate SREBP-1 and its regulated key genes ACC, FAS and LDLR as novel molecular targets in cancer. Dr. Guo's work is committed to unraveling how EGFR/PI3K signaling regulates metabolism network, to unravel the link between glucose uptake and lipid metabolism, to identify the key molecular targets in this network and develop potent inhibitors to translate into clinical trial to eradicate cancer cells.

Current Publications

  • Ru P, Williams TM, Chakravarti A, Guo DTumor metabolism of malignant gliomas.Cancers (Basel) 5 1469-84 11/8/2013
  • Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PSThe mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.Clin Cancer Res 19 5722-32 10/15/2013
  • Guo D, Bell EH, Mischel P, Chakravarti ATargeting SREBP-1-driven Lipid Metabolism to Treat Cancer.Curr Pharm Des in press 6/25/2013
  • Guo D, Bell EH, Chakravarti ALipid metabolism emerges as a promising target for malignant glioma therapy.CNS Oncol 2(3) 289-299 5/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: